Information  X 
Enter a valid email address

Renalytix AI PLC (RENX)

  Print      Mail a friend

Monday 30 September, 2019

Renalytix AI PLC

Result of AGM

RNS Number : 2137O
Renalytix AI PLC
30 September 2019
 

Renalytix AI plc

("RenalytixAI" or the "Company")

 

Result of AGM

 

Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces at its annual general meeting held earlier today, the following resolutions were passed on a show of hands with the table below summarising proxy votes:

 


Resolution

Votes for*

Votes against

Votes withheld

1.  

To receive the audited accounts of the Company

24,481,789

 

22

0

2.  

To re-elect Julian Baines

24,481,789

 

22

0

3.  

To re-elect Christopher Mills

20,570,985

 

3,910,826

 

0

4.  

To re-elect Richard Evans

24,481,789

 

22

 

0

5.  

To re-elect Fergus Fleming

24,481,789

 

22

0

6.  

To elect Doctor Erik Lium

24,481,789

 

22

0

7.  

To elect James McCullough

24,481,789

 

22

0

8.  

To elect Barbara Murphy

24,481,811

 

0

0

9.  

To re-appoint the auditors PKF Littlejohn LLP and authorise the Directors to fix their remuneration

24,481,789

 

22

0

10.

To authorise the directors to replace the existing authority to allot shares in the Company in connection with s551 of the Companies Act 2006

24,481,789

 

22

0

11.

To authorise the directors to allot Relevant Securities as if s561 of the Companies Act 2006 did not apply

23,769,147

 

702,664

 

10,000

 

*Any proxy appointments, which gave discretion to the Chairman have been included in the 'For' votes total.

 

For further information, please contact:

 

Renalytix AI plc 

www.renalytixai.com

James McCullough, CEO

Via Walbrook PR



Stifel (Nominated Adviser & Joint Broker)

Tel: 020 7710 7600

Alex Price / Jonathan Senior / Ben Maddison

 




N+1 Singer (Joint Broker)

Tel: 020 7496 3000

Aubrey Powell / James White / George Tzimas (Corporate Finance)
Tom Salvesen
/ Mia Gardner (Corporate Broking)








Walbrook PR Limited

Tel: 020 7933 8780 or [email protected]

Paul McManus / Lianne Cawthorne

Mob: 07980 541 893 / 07584 391 303

 

About Kidney Disease 

Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. In the United States alone, over 40 million people are classified as having chronic kidney disease, with nearly 50 percent of individuals with advanced (Stage IV) disease unaware of the severity of their reduced kidney function. As a result, many patients progress to kidney failure in an unplanned manner, ending up having dialysis in the emergency room without ever seeing a clinical specialist, such as a nephrologist. Every day 13 patients die in the United States while waiting for a kidney transplant.

 

About RenalytixAI

RenalytixAI is a developer of artificial intelligence-enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company's solutions are being designed to make significant improvements in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit renalytixai.com.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
RAGEASNEDDANEFF

a d v e r t i s e m e n t